Enlivex (ENLV) has released an update.
Enlivex Therapeutics Ltd. has initiated a pivotal Phase I/II trial for Allocetra, marking a significant stride in potentially treating thumb osteoarthritis, a condition with no current FDA-approved treatments. The trial will evaluate the safety and effectiveness of Allocetra injections in patients who have not responded to conventional therapies, with plans to enroll up to 46 participants. Enlivex’s Allocetra therapy aims to restore macrophage homeostasis, offering a novel approach to treating a variety of severe and debilitating diseases.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
